JP2019519586A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519586A5
JP2019519586A5 JP2018568791A JP2018568791A JP2019519586A5 JP 2019519586 A5 JP2019519586 A5 JP 2019519586A5 JP 2018568791 A JP2018568791 A JP 2018568791A JP 2018568791 A JP2018568791 A JP 2018568791A JP 2019519586 A5 JP2019519586 A5 JP 2019519586A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
haloalkyl
hydroxyalkyl
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519586A (ja
JP7231414B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039646 external-priority patent/WO2018005591A1/en
Publication of JP2019519586A publication Critical patent/JP2019519586A/ja
Publication of JP2019519586A5 publication Critical patent/JP2019519586A5/ja
Application granted granted Critical
Publication of JP7231414B2 publication Critical patent/JP7231414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568791A 2016-06-29 2017-06-28 ビアリールメチルヘテロサイクル Active JP7231414B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356215P 2016-06-29 2016-06-29
US62/356,215 2016-06-29
PCT/US2017/039646 WO2018005591A1 (en) 2016-06-29 2017-06-28 Biarylmethyl heterocycles

Publications (3)

Publication Number Publication Date
JP2019519586A JP2019519586A (ja) 2019-07-11
JP2019519586A5 true JP2019519586A5 (enExample) 2020-12-17
JP7231414B2 JP7231414B2 (ja) 2023-03-01

Family

ID=59297443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568791A Active JP7231414B2 (ja) 2016-06-29 2017-06-28 ビアリールメチルヘテロサイクル

Country Status (16)

Country Link
US (2) US11407733B2 (enExample)
EP (1) EP3478672B1 (enExample)
JP (1) JP7231414B2 (enExample)
KR (1) KR102538999B1 (enExample)
CN (1) CN109715615A (enExample)
AR (1) AR108906A1 (enExample)
AU (1) AU2017289974B2 (enExample)
BR (1) BR112018077075A2 (enExample)
CA (1) CA3029630A1 (enExample)
EA (1) EA039493B1 (enExample)
ES (1) ES2984389T3 (enExample)
IL (1) IL263499B (enExample)
MX (1) MX2018015247A (enExample)
SG (1) SG11201810837QA (enExample)
TW (1) TW201811759A (enExample)
WO (1) WO2018005591A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461822B1 (en) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof
CA3072362A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
CN119751456A (zh) 2018-04-16 2025-04-04 C4医药公司 螺环化合物
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
MY209034A (en) 2018-10-05 2025-06-17 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
AU2020294781B2 (en) * 2019-06-20 2025-10-09 Chemocentryx, Inc. Compounds for treatment of PD-L1 diseases
CN110479182A (zh) * 2019-09-10 2019-11-22 肯特催化材料股份有限公司 一种多氨基双子表面活性剂及其制备方法与应用
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
PE20241304A1 (es) * 2021-07-30 2024-06-24 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o senalizacion mediada por at2r
CN115321495B (zh) * 2022-07-28 2023-07-21 东北石油大学 一种金属富氮化合物FeN8的合成方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO811630L (no) 1980-05-29 1981-11-30 Bayer Ag Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5223499A (en) 1989-05-30 1993-06-29 Merck & Co., Inc. 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5411980A (en) 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
US5140037A (en) 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
CA2085584C (en) 1990-06-22 2003-02-11 David John Carini Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5798364A (en) 1992-03-26 1998-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines
TW274551B (enExample) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
WO1992020662A1 (en) 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
CA2072775A1 (en) 1991-07-03 1993-01-04 Wallace T. Ashton Substituted triazolinones
WO1993003033A1 (en) 1991-07-26 1993-02-18 G. D. Searle & Co. CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
JPH06510763A (ja) 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン2受容体遮断イミダゾリノン誘導体
AU2496492A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
CA2077420C (en) 1991-09-10 1998-08-25 Yasushi Honma Imidazoindolizine derivatives and process for preparation thereof
IL103020A (en) 1991-09-10 1998-10-30 Tanabe Seiyaku Co 3-(1,1'-Biphenyl-4-yl-methyl)-4,5,6,7-tetrahydro-3h-imidazo Ú4,5-c¾ pyridine-4-carboxylic acids their preparation and pharmaceutical compositions containing them
WO1993019067A1 (en) 1991-09-12 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine derivatives as angiotensin ii antagonists
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
GB2263637A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
EP0649424B1 (en) 1992-07-10 1998-10-07 Knoll AG Dioxcyclobutene derivatives as angiotensin ii antagonists
US5554625A (en) 1992-07-17 1996-09-10 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
GB2272899A (en) 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
JPH06312926A (ja) 1993-03-04 1994-11-08 Tanabe Seiyaku Co Ltd アンジオテンシンii拮抗薬
DE4320432A1 (de) 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US5424432A (en) 1994-05-26 1995-06-13 Merck & Co., Inc. Process for the preparation of imidazolutidine
RU2166330C2 (ru) 1995-06-07 2001-05-10 Джи. Ди. Сирл Энд Ко. Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона
ES2175098T3 (es) 1995-06-07 2002-11-16 Searle & Co Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo.
WO1996040256A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
IL130599A0 (en) 1997-01-10 2000-06-01 Merck & Co Inc Use of angiotensin II antagonists to treat symptomatic heart failure
EP1059843A1 (en) 1998-02-25 2000-12-20 Merck & Co., Inc. Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist
GB2337701A (en) 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB0014861D0 (en) 2000-06-16 2000-08-09 Pharmacia & Upjohn Spa Novel telomerase inhibitors
DE10112041A1 (de) 2001-03-14 2002-09-26 Aventis Pharma Gmbh p-Thienylbenzyl-Amide als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
JP2003034684A (ja) 2001-06-29 2003-02-07 Biofor Inc 新規な種類の抗真菌剤
WO2003064414A1 (en) 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20060211866A1 (en) 2005-03-21 2006-09-21 Glenmark Pharmaceuticals Limited Process for the preparation of angiotensin receptor blockers and intermediates thereof
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20110269717A1 (en) 2006-07-17 2011-11-03 Braincells Inc. Neurogenesis by modulating angiotensin
EP2081888A1 (en) 2006-09-08 2009-07-29 Novartis AG N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
SI2376101T1 (sl) 2008-12-29 2016-02-29 Trevena, Inc. Efektorji beta-arestina in sestavki ter metode za njihovo uporabo
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
CN102816126A (zh) 2011-06-07 2012-12-12 中国药科大学 具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
DE102012004589A1 (de) 2012-03-09 2013-09-12 Forschungszentrum Jülich GmbH Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen
US9624181B2 (en) 2012-08-31 2017-04-18 Api Corporation Method for producing biaryl compound
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
US9943509B2 (en) 2013-03-15 2018-04-17 University Of Southern California Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia

Similar Documents

Publication Publication Date Title
JP2019519586A5 (enExample)
JP2020507582A5 (enExample)
JP2015514808A5 (enExample)
RU2430923C2 (ru) Тиазолилдигидрохиназолины
ME02373B (me) Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze
JP2012525431A5 (enExample)
ES2552684T3 (es) Nuevos compuestos de imidazolidina como moduladores del receptor de andrógenos
JP2009536620A5 (enExample)
JP2016520618A5 (enExample)
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
RU2018104092A (ru) Бициклические лактамы и способы их применения
RU2009115963A (ru) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
JP2012525332A5 (enExample)
JP2014516074A5 (enExample)
RU2013151803A (ru) Бициклические гетероциклические соединения и их применения в терапии
JP2009530424A5 (enExample)
JP2017507122A5 (enExample)
JP2011520832A5 (enExample)
JP2019507114A5 (enExample)
RU2009117705A (ru) Производные 2-аминокарбонилпиридина
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
JP2011526917A5 (enExample)
JP2019512535A5 (enExample)
RU2008123388A (ru) Соединения и композиции в качестве модуляторов lxr
JP2013542267A5 (enExample)